![]() ![]() The Metoprolol Atherosclerosis Prevention in Hypertensives (MAPHY) trial specifically showed the benefit of metoprolol over diuretics regarding sudden cardiac death as well as myocardial infarction. Several randomized trials in the 1980s showed a mortality benefit for beta-blockers in acute myocardial infarction. The role of beta-blockers as initial therapy for hypertension, particularly in the absence of compelling indications, has been questioned. There is also conflicting evidence regarding the optimal selection of a particular beta-blocker in treating each specific disease. There are immediate and extended-release preparations available orally. There is controversy regarding the selection of beta-blockers in the management of the above conditions. Both oral and intravenous preparations are available. Off-label uses include supraventricular tachycardia and thyroid storm. Metoprolol is FDA-approved to treat angina, heart failure, myocardial infarction, atrial fibrillation/flutter, and hypertension. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |